Print Friendly, PDF & Email

NCT/Study#

NCT04613596 /

849-007

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

DISEASE GROUP:

Phase 1 Clinical Trials

current phase:

Phase II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587